Mian Muhammad Umar, Afzal Mishal, Butt Aqsa A, Ijaz Muniba, Khalil Kashaf, Abbasi Maryam, Fatima Marhaba, Asif Mariam, Nadeem Saad, Jha Shivangi, Panjiyar Binay K
Internal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
Cureus. 2024 Sep 9;16(9):e69028. doi: 10.7759/cureus.69028. eCollection 2024 Sep.
Neuropathic pain, a debilitating condition, remains challenging to manage effectively. An insight into neuropharmacological mechanisms is critical for optimizing treatment strategies. This systematic review aims to evaluate the role of neuropharmacological agents based on their efficacy, involved neurotransmitters, and receptors. A manual literature search was undertaken in PubMed including Medline, Cochrane Library, Google Scholar, Plos One, Science Direct, and clinicaltrials.gov from 2013 until 2023. Out of the 13 included studies, seven evaluated the role of gabapentinoids. Two main drugs from this group, gabapentin and pregabalin, function by binding voltage-gated calcium channels, lowering neuronal hyperexcitability and pain signal transmission, thereby relieving neuropathic pain. Four of the pooled studies reported the use of tricyclic antidepressants (TCAs) including amitriptyline and nortriptyline which work by blocking the reuptake of norepinephrine and serotonin, their increased concentration is thought to be central to their analgesic effect. Three articles assessed the use of serotonin-norepinephrine reuptake inhibitors (SNRIs) and reported them as effective as the TCAs in managing neuropathic pain. They work by augmenting serotonin and norepinephrine. Three studies focused on the use of selective serotonin reuptake inhibitors (SSRIs), modulating their effect by increasing serotonin levels; however, they were reported as not a highly effective treatment option for neuropathic pain. One of the studies outlined the use of cannabinoids for neuropathic pain by binding to cannabinoid receptors with only mild adverse effects. It is concluded that gabapentinoids, TCAs, and SNRIs were reported as the most effective therapy for neuropathic pain; however, for trigeminal neuralgia, anticonvulsants like carbamazepine were considered the most effective. Opioids were considered second-line drugs for neuropathic pain as they come with adverse effects and a risk of dependence. Ongoing research is exploring novel drugs like ion channels and agents modulating pain pathways for neuropathic pain management. Our review hopes to inspire further research into patient stratification by their physiology, aiding quicker and more accurate management of neuropathic pain while minimizing inadvertent side effects.
神经性疼痛是一种使人衰弱的病症,有效管理起来仍然具有挑战性。深入了解神经药理学机制对于优化治疗策略至关重要。本系统综述旨在根据神经药理学药物的疗效、涉及的神经递质和受体来评估其作用。我们在PubMed(包括Medline、Cochrane图书馆、谷歌学术、Plos One、Science Direct和clinicaltrials.gov)上进行了手动文献检索,检索时间跨度为2013年至2023年。在纳入的13项研究中,有7项评估了加巴喷丁类药物的作用。该类药物中的两种主要药物加巴喷丁和普瑞巴林,通过与电压门控钙通道结合发挥作用,降低神经元的过度兴奋性和疼痛信号传递,从而缓解神经性疼痛。汇总研究中的四项报告了三环类抗抑郁药(TCAs)的使用情况,包括阿米替林和去甲替林,它们通过阻断去甲肾上腺素和5-羟色胺的再摄取发挥作用,人们认为它们浓度的增加是其镇痛作用的关键。三篇文章评估了5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRIs)的使用情况,并报告它们在管理神经性疼痛方面与三环类抗抑郁药一样有效。它们通过增加5-羟色胺和去甲肾上腺素发挥作用。三项研究聚焦于选择性5-羟色胺再摄取抑制剂(SSRIs)的使用,通过提高5-羟色胺水平来调节其效果;然而,据报道它们并非治疗神经性疼痛的高效选择。其中一项研究概述了大麻素通过与大麻素受体结合用于治疗神经性疼痛,且仅有轻微不良反应。研究得出结论,加巴喷丁类药物、三环类抗抑郁药和5-羟色胺-去甲肾上腺素再摄取抑制剂被报告为治疗神经性疼痛最有效的疗法;然而,对于三叉神经痛,像卡马西平这样的抗惊厥药被认为是最有效的。阿片类药物被视为治疗神经性疼痛的二线药物,因为它们存在不良反应和成瘾风险。正在进行的研究正在探索如离子通道等新型药物以及调节神经性疼痛通路的药物用于神经性疼痛管理。我们的综述希望激发进一步根据患者生理特征进行分层研究,有助于更快速、准确地管理神经性疼痛,同时将意外副作用降至最低。